News coverage about Bio-Techne Corp (NASDAQ:TECH) has trended somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Bio-Techne Corp earned a coverage optimism score of 0.14 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 46.5532344138873 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

These are some of the headlines that may have impacted Accern Sentiment’s scoring:

TECH has been the topic of several recent analyst reports. Zacks Investment Research raised Bio-Techne Corp from a “hold” rating to a “buy” rating and set a $131.00 price target on the stock in a research note on Thursday, July 6th. Deutsche Bank AG reaffirmed a “buy” rating and issued a $122.00 price target (up previously from $115.00) on shares of Bio-Techne Corp in a research note on Wednesday, May 3rd. BidaskClub lowered Bio-Techne Corp from a “buy” rating to a “hold” rating in a research note on Sunday, July 16th. Wells Fargo & Company initiated coverage on Bio-Techne Corp in a research note on Thursday, July 13th. They issued a “market perform” rating on the stock. Finally, TheStreet raised Bio-Techne Corp from a “c+” rating to a “b” rating in a research note on Tuesday, May 2nd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $125.20.

Bio-Techne Corp (TECH) opened at 117.54 on Friday. Bio-Techne Corp has a 52 week low of $95.68 and a 52 week high of $121.94. The stock has a 50 day moving average price of $116.63 and a 200 day moving average price of $108.89. The firm has a market cap of $4.39 billion, a price-to-earnings ratio of 57.06 and a beta of 0.79.

Bio-Techne Corp (NASDAQ:TECH) last released its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported $1.09 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.99 by $0.10. Bio-Techne Corp had a return on equity of 14.18% and a net margin of 12.93%. The business had revenue of $156.60 million for the quarter, compared to analysts’ expectations of $150.25 million. During the same quarter in the previous year, the firm posted $0.92 earnings per share. The company’s revenue was up 16.2% compared to the same quarter last year. Equities research analysts expect that Bio-Techne Corp will post $3.98 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 1st. Investors of record on Friday, August 18th will be paid a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 1.09%. The ex-dividend date is Wednesday, August 16th. Bio-Techne Corp’s dividend payout ratio (DPR) is 65.98%.

In related news, Director Charles A. Dinarello sold 5,000 shares of the business’s stock in a transaction dated Wednesday, May 31st. The stock was sold at an average price of $111.37, for a total value of $556,850.00. Following the transaction, the director now owns 12,473 shares in the company, valued at $1,389,118.01. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In the last quarter, insiders sold 10,200 shares of company stock worth $1,135,648. Insiders own 2.70% of the company’s stock.

WARNING: This report was first reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another website, it was stolen and republished in violation of United States & international trademark and copyright legislation. The legal version of this report can be viewed at

About Bio-Techne Corp

Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through three segments: Biotechnology, Clinical Controls and Protein Platforms. The Biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products, such as cytokines, growth factors, immunoassays, antibodies and related reagents, across the world.

Insider Buying and Selling by Quarter for Bio-Techne Corp (NASDAQ:TECH)

Receive News & Ratings for Bio-Techne Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.